Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited

TLPPF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.94B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Telix Pharmaceuticals LimitedTelix Pharmaceuticals Limited96.2-13%1.21.2
$22.00

Target Price by Analysts

154% upsideTelix Pharmaceuticals Limited Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2.94 Billion
Enterprise Value$3.27 Billion
Earnings per Share$-0.02
Beta0.6
Outstanding Shares339,220,212

Return

Return on Equity13.12%ROE
Return on Assets4.70%
Return on Invested Capital6.03%

Valuation & Multiples

P/E Ratio96.23P/E Ratio
PEG-5.77PEG
Price to Sales1.24Price to Sales
Price to Book Ratio8.66Price to Book Ratio
Enterprise Value to Revenue1.31
Enterprise Value to EBIT48.41
Enterprise Value to Net Income51
Total Debt to Enterprise0.18
Debt to Equity1.19Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 19, 2026
EPS
$0.11
Est. $0.04
Revenue
$477.00 M
Est. $479.63 M

Next Earnings Call

Expected Date
February 19, 2027
EPS Estimate
-$0.04
Consensus analyst estimate
Revenue Estimate
$493.84 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Telix Pharmaceuticals Limited

1,184 employees
CEO: Christian Behrenbruch

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medi...

Questions & Answers